Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

This study tests whether continuing encorafenib and cetuximab (a targeted therapy combination for colorectal cancer with a BRAF V600E mutation) plus adding FOLFIRI chemotherapy can still help patients whose colorectal cancer progressed while on encorafenib and cetuximab alone — a strategy known as "treatment beyond progression." **You may be eligible if...** - You are 18 or older with metastatic colorectal cancer confirmed to have the BRAF V600E mutation - You previously received encorafenib + cetuximab as second-line therapy and had at least some benefit (complete response, partial response, or stable disease for at least 3 months) - Your cancer has now progressed while on that treatment - You are healthy enough to receive additional chemotherapy (ECOG ≤ 1) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have a microsatellite instability-high (MSI-H) or mismatch repair-deficient tumor - You are pregnant or breastfeeding - You have a life expectancy of less than 3 months - You have uncontrolled infections or serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.